These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6666180)

  • 1. [Drug therapy of hyperprolactinemia, acromegaly and Cushing syndrome].
    Marek J; Rezábek K; Srámková J
    Z Gesamte Inn Med; 1983 Nov; 38(22):246-8. PubMed ID: 6666180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of hyperprolactinemia and acromegaly with lisuride].
    Berezin M; Elchalal U; Olchovsky D
    Harefuah; 1989 Jun; 116(12):634-7. PubMed ID: 2792946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of lysenyl-forte treatment in acromegaly and hyperprolactinemia syndrome].
    Balabolkin MI; Gerasimov GA; Snigireva RIa; Gorokhova TR
    Klin Med (Mosk); 1989 Sep; 67(9):89-92. PubMed ID: 2586051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of dironyl in the treatment of acromegaly and hyperprolactinemia].
    Felt V; Nedvídková J
    Vnitr Lek; 1985 Oct; 31(10):980-5. PubMed ID: 4090298
    [No Abstract]   [Full Text] [Related]  

  • 5. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of lisuride in the treatment of hyperprolactinemic amenorrhea.
    Rojanasakul A; Sirimongkolkasem R; Chailurkit LO
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():42-6. PubMed ID: 2351912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.
    Dallabonzana D; Liuzzi A; Oppizzi G; Cozzi R; Verde G; Chiodini P; Rainer E; Dorow R; Horowski R
    J Clin Endocrinol Metab; 1986 Oct; 63(4):1002-7. PubMed ID: 3745401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Terguride in the treatment of hyperprolactinemia and acromegaly].
    Marek J; Bauer J; Srámková J; Hána V
    Cas Lek Cesk; 1986 Jan; 125(4):100-5. PubMed ID: 3948223
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.
    Stracke H; Heinlein W; Horowski R; Schatz H
    Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy].
    Brabant G; Brennecke I; Herrmann H; Friedrich H; Wagner TO; von zur Mühlen A; Hesch RD
    Dtsch Med Wochenschr; 1985 Oct; 110(41):1564-7. PubMed ID: 4042883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
    Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
    J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of acromegaly with lisuride: differences of effect on growth hormone and somatomedin.
    Marek J; Srámková J; Schüllerová M; Stĕpán J; Schreiberová O
    Endokrinologie; 1981 Dec; 78(2-3):175-85. PubMed ID: 7037372
    [No Abstract]   [Full Text] [Related]  

  • 13. [Determination of growth hormone response to thyreoliberin in the evaluation of lisuride therapy of acromegaly].
    Felt V; Nedvídková J
    Vnitr Lek; 1982 Aug; 28(8):756-61. PubMed ID: 6814061
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lisurid in the treatment of hyperprolactinemia: comments on the article by J. Presl].
    Pospísil O
    Cesk Gynekol; 1980 Nov; 45(9):679-81. PubMed ID: 7197199
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of short and long-term administration of lisuride in Cushing's disease.
    Boscaro M; Merola G; Serafini E; Mantero F
    J Endocrinol Invest; 1985 Feb; 8(1):13-7. PubMed ID: 2985685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperprolactinemia syndrome in men].
    Balabolkin MI; Gerasimov GA; Gorokhova TR; Liubimov AV
    Sov Med; 1990; (4):23-6. PubMed ID: 2374967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis.
    Mukherjee A; Murray RD; Columb B; Gleeson HK; Shalet SM
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):743-8. PubMed ID: 14974916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary excretion of free catecholamines in long-term treatment with dopaminergic agonists.
    Marek J; Kopecká J
    Exp Clin Endocrinol; 1984 Oct; 84(2):183-90. PubMed ID: 6151906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical treatment of hyperprolactinaemic disorders.
    Ferrari C; Crosignani PG
    Hum Reprod; 1986 Dec; 1(8):507-14. PubMed ID: 3546358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of lisuride hydrogen maleate in the hyperprolactinaemia-amenorrhoea syndrome: clinical and hormonal responses.
    De Cecco L; Foglia G; Ragni N; Rossato P; Venturini PL
    Clin Endocrinol (Oxf); 1978 Dec; 9(6):491-8. PubMed ID: 106990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.